title: Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
abstract: Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.
authors.affiliation: Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France.
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
authors.affiliation: Med Ed, RMC, Exeter, UK.
authors.forename: C
authors.initials: C
authors.lastname: Jenkins
authors.affiliation: Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca.
authors.forename: I F
authors.initials: IF
authors.lastname: Tannock
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D009919:Orchiectomy; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D059039:Standard of Care; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone
keywords: ADT; de novo metastatic; docetaxel; hormone-naive; prostate